logo

For the Inventor, By the Inventor

Blue Bell, PA, United States of America

Dong-Mei Feng

This inventor holds 18 USPTO granted patents. Top assignees: Merck + Co., Inc., The Administrators of the Tulane Educational Fund, The University of Texas System. Active years: 1990-2006.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Dong-Mei Feng. Retrieved from https://idiyas.com/inventor/dong-mei-feng

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 18

% Patents Active = 100.0

Average Co-Inventor Count = 5.2

ph-index = 9

Forward Citations = 420(Granted Patents)


Location History:

  • Austin, TX (US) (1990 - 1995)
  • Lansdale, PA (US) (1998)
  • Harleysville, PA (US) (1995 - 2000)
  • Rahway, NJ (US) (2000 - 2002)
  • Blue Bell, PA (US) (1998 - 2006)

Company Filing History:

goldMedal14 out of 4,770 
 
Merck + Co., Inc.
 patents
silverMedal3 out of 249 
 
The Administrators of the Tulane Educational Fund
 patents
bronzeMedal3 out of 5,638 
 
The University of Texas System
 patents
4. 1 out of 834,513 
Other
 patents
where one patent can have more than one assignee

Years Active: 1990-2006

Loading Chart...
18 patents (USPTO):Explore Patents
1. 7091380 - N-biphenylmethyl aminocycloalkanecarboxamide derivatives (2006-08-15),
2. 6919343 - N-biphenyl(substituted methyl) aminocycloalkane-carboxamide derivatives (2005-07-19),
3. 6391305 - Conjugates useful in the treatment of prostate cancer (2002-05-21),
4. 6174858 - Conjugates useful in the treatment of prostate cancer (2001-01-16),
5. 6143864 - Peptides (2000-11-07),
6. 6130204 - Peptides (2000-10-10),
7. 5998362 - Conjugates useful in the treatment of prostate cancer (1999-12-07),
8. 5948750 - Conjugates useful in the treatment of prostate cancer (1999-09-07),
9. 5866679 - Peptides (1999-02-02),
10. 5763404 - Methods for using LHRH antagonists with low histamine release (1998-06-09),
11. 5714485 - Piperidine and hexahydropyridazine thrombin inhibitors (1998-02-03),
12. 5681926 - Thrombin receptor binding peptides (1997-10-28),
13. 5672582 - Thrombin inhibitors (1997-09-30),
14. 5510369 - Pyrrolidine thrombin inhibitors (1996-04-23),
15. 5480969 - Antagonists of LHRH (1996-01-02),

Title: Dong-Mei Feng: A Pioneer in Inventing Bradykinin B1 Antagonists

Introduction

Dong-Mei Feng, a prolific inventor hailing from Blue Bell, PA, has made significant contributions to the field of medicine through his groundbreaking inventions. With a total of 18 patents to his name, Dong-Mei Feng is a trailblazer in the world of pharmaceutical innovation.

Latest Patents

Among his latest patents are the N-biphenyl(substituted methyl) aminocycloalkanecarboxamide derivatives. These inventions serve as bradykinin B1 antagonists or inverse agonists, playing a crucial role in treating or preventing symptoms such as pain and inflammation associated with the bradykinin B1 pathway.

Career Highlights

Dong-Mei Feng has left an indelible mark on renowned companies such as Merck & Company, Inc. and the University of Texas System. His work at these esteemed institutions showcases his expertise and dedication to advancing medical research and technology.

Collaborations

Throughout his career, Dong-Mei Feng has collaborated with esteemed professionals in the field, including Victor M. Garsky and Raymond E. Jones. These collaborations have led to groundbreaking discoveries and have further solidified Dong-Mei Feng's reputation as a leader in pharmaceutical innovation.

Conclusion

In conclusion, Dong-Mei Feng stands as a beacon of innovation in the field of inventing bradykinin B1 antagonists. His relentless pursuit of excellence and passion for creating a better future through technology make him a true pioneer in the industry. Dong-Mei Feng's impact will undoubtedly be felt for generations to come, shaping the future of medicine and pharmaceutical innovations.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…